TABLE IV. Test properties calculated after creating a 2 x 2 table.
Reference | Casesa | Controlsb | Sensitivity (95% CI) | Specificity (95% CI) | PPV (95% CI) | NPV (95% CI) | Accuracy (95% CI) |
---|---|---|---|---|---|---|---|
Piñero et al. (1999) | 36 (30) | 19 (0) | 83.33 (68.11-92.13) | 100 (83.18-100) | 100 (88.65-100) | 76.00 (56.57-88.5) | 89.09 (78.17-94.9) |
Pirmez et al. (1999) | 30 (23) | 14 (0) | 76.67 (59.07-88.21) | 100 (78.47-100) | 100 (85.69-100) | 66.67 (45.37-82.81) | 84.09 (70.63-92.07) |
Victoir et al. (2003) | 15 (11) | 5 (0) | 73.33 (48.05-89.1) | 100 (56.55-100) | 100 (74.12-100) | 55.56 (26.66-81.12) | 80 (58.4-91.03) |
Disch et al. (2005) 51 c | 13 (11) | 10 (0) | 84.62 (57.76-95.67) | 100 (75.25-100) | 100 (74.12-100) | 83.33 (55.2-95.3) | 91.3 (73.2-97.58) |
Disch et al. (2005) 120 c | 13 (11) | 10 (0) | 84.62 (57.76-95.67) | 100 (75.25-100) | 100 (74.12-100) | 83.33 (55.2-95.3) | 91.3 (73.2-97.58) |
Camera et al. (2006) | 20 (7) | 37 (9) | 35 (18.12-56.71) | 75.68 (59.88-86.64) | 43.75 (23.1-66.82) | 68.29 (53.02-80.44) | 61.4 (48.43-72.94) |
Bracho et al. (2007) kDNA d | 35 (24) | 25 (2) | 68.57 (52.02-81.45) | 92 (75.03-97.78) | 92.31 (75.86-97.86) | 67.65 (50.84-80.87) | 78.33 (66.38-86.88) |
Bracho et al. (2007) ITS d | 35 (14) | 25 (1) | 40 (25.55-56.43) | 96 (80.46-99.29) | 93.33 (70.18-98.81) | 53.33 (39.08-67.07) | 63.33 (50.68-74.38) |
Deborggraeve et al. (2008) | 12 (11) | 8 (0) | 91.67 (64.61-98.51) | 100 (67.56-100) | 100 (74.12-100) | 88.89 (56.5-98.01) | 95 (76.39-99.11) |
Pereira et al. (2008) | 14 (12) | 3 (0) | 85.71 (60.06-95.99) | 100 (43.85-100) | 100 (75.15-100) | 60 (23.07-88.24) | 88.24 (65.66-96.71) |
Fagundes et al. (2010) | 15 (14) | 15 (1) | 93.33 (70.18-98.81) | 93.33 (70.18-98.81) | 93.33 (70.18-98.81) | 93.33 (70.18-98.81) | 93.33 (78.68-98.15) |
Boggild et al. (2011) Cervisoft ® | 23 (22) | 10 (1) | 95.65 (79.01-99.23) | 90 (59.58-98.21) | 95.65 (79.01-99.23) | 90 (59.58-98.21) | 93.94 (80.39-98.32) |
Boggild et al. (2011) Hystobrush ® | 23 (21) | 10 (1) | 91.3 (73.20-97.58) | 90 (59.58-98.21) | 95.45 (78.20-99.19) | 81.82 (52.30-94.86) | 90.91 (76.43-96.86) |
Boggild et al. (2011) Biopsy e | 23 (22) | 5 (0) | 95.65 (70.01-99.23) | 100 (56.55-100) | 100 (85.13-100) | 83.33 (43.65-96.99) | 96.43 (82.29-99.37) |
Thomaz-Soccol et al. (2011) MP1L/MP3H f | 15 (15) | 6 (0) | 100 (79.61-100) | 100 (60.97-100) | 100 (79.61-100) | 100 (60.97-100) | 100 (84.54-100) |
Thomaz-Soccol et al. (2011) B1/B2 f | 15 (15) | 6 (0) | 100 (79.61-100) | 100 (60.97-100) | 100 (79.61-100) | 100 (60.97-100) | 100 (84.54-100) |
Veland et al. (2011) | 8 (6) | 32 (0) | 75 (43.93-92.85) | 100 (89.28-100) | 100 (60.97-100) | 94.12 (80.91-98.37) | 95 (83.5-98.62) |
Marco et al. (2012) | 9 (8) | 19 (3) | 88.89 (56.5-98.01) | 84.21 (62.43-94.48) | 72.73 (43.43-90.25) | 94.12 (73.02-98.95) | 85.71 (68.51-94.3) |
Neitzke-Abreu et al. (2013) Blood e | 10 (6) | 117 (2) | 60 (31.27-83.18) | 98.29 (93.98-99.53) | 75 (40.93-92.85) | 96.64 (91.68-98.69) | 95.28 (90.08-97.82) |
Gomes et al. (2014a) Biopsy e | 13 (8) | 30 (0) | 61.54 (35.52-82.29) | 100 (88.65-100) | 100 (67.56-100) | 85.71 (70.62-93.74) | 88.37 (75.52-94.93) |
a: true positives; b: false positives; c: amplicon size; d: polymerase chain reaction target; e: collected material; f: primers; CI: confidence interval; NPV: negative predictive value; PPV: positive predictive value. Publications with more than one collection or amplification method were subdivided.